Allergan announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application for ubrogepant, a highly potent oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in adults.
The supplemental New Drug Application (sNDA) for Emgality (galcanezumab-gnlm; Lilly) has been granted Priority Review by the Food and Drug Administration (FDA) for the preventive treatment of episodic cluster headache in adults.
Although the quality of evidence is low due to variable study designs, botulinum toxin may be beneficial in the treatment of chronic tension-type headaches for specific patients with clear treatment goals.
The FDA has granted marketing clearance for eNeura’s single-pulse transcranial magnetic stimulation (sTMS) device for use in patients ≥12 years for the acute and prophylactic treatment of migraine.
Alder BioPharmaceuticals has submitted a Biologics License Application to the Food and Drug Administration (FDA) for eptinezumab, an investigational monoclonal antibody (mAB) for migraine prevention.
Tosymra is an intranasal spray containing sumatriptan 10mg, a selective 5-HT1B/1D receptor agonist.
At 3 months, the researchers found a tendency in favor of botulinum toxin over placebo, with a mean difference in the change of migraine frequency of −0.23 (95% confidence interval, −0.47 to 0.02; P=.08).
The FOCUS study enrolled a total of 838 patients who experienced chronic or episodic migraines and had inadequate responses (defined as lack of efficacy after at least 3 months of therapy; or the patient cannot tolerate the drug; or the drug is contraindicated; or the drug is not suitable for the patient) to other classes of drugs (ie, beta-blockers, anticonvulsants, tricyclics, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, valproic acid).
Surgery to remove nasal mucus contact points could reduce symptoms in patients with chronic headache.
Migraine with aura is associated with an elevated risk for incident atrial fibrillation, according to a new study.
